What the evidence actually demands
A key principle: most nootropic research is conducted in people with cognitive impairment or deficiency states. A compound that improves memory in mild cognitive impairment (MCI) patients or in choline-deficient animals does not necessarily improve cognition in a well-nourished, cognitively healthy adult. This distinction — efficacy in clinical populations vs. efficacy as a cognitive enhancer in healthy people — is almost never made clearly in marketing. The bar for recommending a compound to a healthy adult should be higher than its ability to reverse a deficit.
Lion's mane (Hericium erinaceus)
Lion's mane is a medicinal mushroom with the most compelling human evidence among botanical nootropics. The mechanism is well-characterised: it contains hericenones and erinacines that stimulate Nerve Growth Factor (NGF) synthesis. A 2023 parallel-group RCT published in the Journal of Alzheimer's Disease (n=77, age 50–80 with mild cognitive impairment, 12 weeks, 1,050 mg/day) found significant improvements in composite cognitive scores and short-term memory versus placebo, with effect sustained at 4-week post-supplementation follow-up.
In healthy adults, evidence is thinner. A 2020 double-blind RCT (n=41, young adults) found lion's mane supplementation (1,800 mg/day for 28 days) improved processing speed but not other cognitive domains. A 2023 Nutrients study in 40 healthy adults found acute dosing improved mood and cognitive performance within 60 minutes. The compound appears safe at doses up to 3,000 mg/day with no serious adverse events reported in clinical trials.
Lion's mane stimulates Nerve Growth Factor and has the strongest human RCT evidence among botanical nootropics. A 2023 trial in adults with mild cognitive impairment found significant memory improvements at 12 weeks that persisted at 4-week follow-up. (Journal of Alzheimer's Disease, 2023)
Bacopa monnieri
Bacopa is an Ayurvedic herb with a genuine evidence base for memory consolidation in adults. The proposed mechanism involves enhanced synaptic communication via bacosides A and B, reduced hippocampal beta-amyloid accumulation (in animal models), and antioxidant activity. A 2012 meta-analysis in the Journal of Ethnopharmacology (9 double-blind placebo-controlled trials) found bacopa consistently improved spatial working memory, information processing speed, and delayed recall versus placebo. A 2023 update (5 additional RCTs) confirmed the finding in adults over 60.
Important caveats: most bacopa trials use 300–450 mg standardised extract (45% bacosides) for at least 12 weeks — shorter trials show weaker effects, consistent with the compound's proposed mechanism of enhancing synaptic protein synthesis over time. Gastrointestinal side effects are common at full doses, particularly without food.
Phosphatidylserine
Phosphatidylserine (PS) is a phospholipid concentrated in neuronal cell membranes, where it plays a role in signal transduction and membrane fluidity. PS levels decline with age. A 2010 Journal of Nutrition, Health & Aging meta-analysis of 12 double-blind RCTs found that PS supplementation (300–400 mg/day) improved cognitive function in older adults with age-associated memory impairment and MCI. The FDA approved a qualified health claim for PS in 2003 in the US, acknowledging suggestive but not conclusive evidence for cognitive decline.
In healthy younger adults, a 2013 Applied Nutrition trial found PS improved cognitive processing speed under stress conditions. This is a more plausible application for healthy adults than general memory enhancement, since the compound's primary benefit appears to be maintaining membrane integrity under metabolic demand.
Omega-3 DHA (revisited as a cognitive compound)
DHA is the dominant structural fatty acid in neuronal membranes — it constitutes approximately 97% of the omega-3 fatty acids in the brain. Cognitive decline is associated with lower brain DHA levels. The COSMOS-Mind trial (3-year RCT, n=2,262) found that combined DHA/EPA supplementation reduced cognitive decline by 18% and significantly improved memory in older adults. A 2022 Cochrane review found consistent evidence that DHA supplementation improves cognitive performance in MCI. Uniquely among nootropics, omega-3 DHA is cheap, safe, evidence-based, and addresses a common genuine deficiency rather than providing pharmacological enhancement.
What does not have adequate evidence in healthy adults
Racetams (piracetam, aniracetam): predominantly studied in dementia or post-stroke populations; no credible RCT evidence for cognitive enhancement in healthy adults at available doses. Modafinil/armodafinil: Schedule 4 prescription drugs in Australia that increase wakefulness — evidence for cognitive enhancement in non-sleep-deprived healthy adults is weak and short-term. Noopept: no peer-reviewed human RCTs in healthy adults published in accessible literature.
For Australians: many nootropic compounds sold in supplements are classified under the TGA's listed medicine framework, which requires only safety evidence — not efficacy. Before spending money on any nootropic, check whether it has at least two positive double-blind RCTs in the population you represent (healthy adult vs. MCI patient) at the dose in the product.
The practical hierarchy
Cognitive longevity starts with foundations: sleep quality (the most powerful cognitive protective factor), cardiovascular fitness (VO2 max independently predicts 10-year cognitive decline), minimising UPF intake, and omega-3 DHA adequacy. Against that foundation, the strongest case for supplementation is: lion's mane for anyone over 50, bacopa for memory consolidation in older adults, and phosphatidylserine if stress-related cognitive symptoms are prominent. These three have the most credible human evidence and good safety profiles.
References
- Saitsu, Y., et al. (2023). Improvement in cognitive function by Hericium erinaceus: parallel-group RCT, n=77. Journal of Alzheimer's Disease.
- Nutrients (2023). Acute effects of lion's mane on mood and cognitive performance in healthy adults.
- Pase, M. P., et al. (2012). Bacopa monnieri for cognitive enhancement: meta-analysis of 9 RCTs. Journal of Ethnopharmacology.
- Journal of Nutrition, Health & Aging (2010). Phosphatidylserine and cognitive function: meta-analysis of 12 RCTs.
- Baker, L. D., et al. (2022). COSMOS-Mind trial: omega-3 and cognitive decline. Alzheimer's & Dementia.
- Cochrane Review (2022). DHA supplementation and cognitive performance in mild cognitive impairment.
- FDA (2003). Qualified health claim for phosphatidylserine and cognitive function.